Spravato is now the first-ever stand-alone therapy for treatment-resistant depression, and is on its way to becoming a blockbuster product.
2d
Inquirer on MSNWorld’s first anti-depression nasal spray receives FDA approvalThe US Food and Drug Administration (FDA) approved the first-ever anti-depression nasal spray, Spravato. The pharmaceutical ...
The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...
Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression for those who had an inadequate response to oral antidepressants.
6d
Live Science on MSNFDA approves 'ketamine' nasal spray for depression — here's everything you need to knowA nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with ...
The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression.
9d
Verywell Health on MSNSpravato Nasal Spray Can Now Be Used Alone for Treatment-Resistant DepressionPeople with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.
The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray ... Johnson. Spravato is the first ...
The expanded indication allows esketamine nasal spray to be used as a standalone treatment in adults with MDD who have not ...
The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult population.
The Food and Drug Administration approved Johnson & Johnson's nasal spray to be used alone in adults ... new major depression treatment to win FDA approval in more than three decades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results